Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality worldwide. Its management encompasses accurate diagnosis, stratification of individual risk and a ...
CAMBRIDGE, Mass., March 28, 2026--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) ...
US-based AI company Anumana has revealed results from a study of an algorithm based on electrocardiogram (ECG) designed to recognise signs of pulmonary hypertension (PH) to expedite diagnosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results